The Experts below are selected from a list of 303 Experts worldwide ranked by ideXlab platform
Lipiski Miriam - One of the best experts on this subject based on the ideXlab platform.
-
Differential leaflet remodeling of bone Marrow Cell pre-seeded versus nonseeded bioresorbable transcatheter pulmonary valve replacements
'Elsevier BV', 2020Co-Authors: Fioretta Emanuela, Mallone Anna, Motta, Sarah E, Von Boehmer Lisa, Dijkman, Pe Petra, Cesarovic Nikola, Caliskan Etem, Rodriguez Cetina Biefer Hector, Lipiski MiriamAbstract:This study showed that bone Marrow mononuclear Cell pre-seeding had detrimental effects on functionality and in situ remodeling of bioresorbable bisurea-modified polycarbonate (PC-BU)-based tissue-engineered heart valves (TEHVs) used as transcatheter pulmonary valve replacement in sheep. We also showed heterogeneous valve and leaflet remodeling, which affects PC-BU TEHV safety, challenging their potential for clinical translation. We suggest that bone Marrow mononuclear Cell pre-seeding should not be used in combination with PC-BU TEHVs. A better understanding of Cell–scaffold interaction and in situ remodeling processes is needed to improve transcatheter valve design and polymer absorption rates for a safe and clinically relevant translation of this approach
-
Differential Leaflet Remodeling of Bone Marrow Cell Pre-Seeded Versus Nonseeded Bioresorbable Transcatheter Pulmonary Valve Replacements
Elsevier, 2020Co-Authors: Fioretta, Emanuela S, Mallone Anna, Motta, Sarah E, Von Boehmer Lisa, Cesarovic Nikola, Caliskan Etem, Rodriguez Cetina Biefer Hector, Lintas Valentina, Dijkman, Petra E, Lipiski MiriamAbstract:This study showed that bone Marrow mononuclear Cell pre-seeding had detrimental effects on functionality and in situ remodeling of bioresorbable bisurea-modified polycarbonate (PC-BU)-based tissue-engineered heart valves (TEHVs) used as transcatheter pulmonary valve replacement in sheep. We also showed heterogeneous valve and leaflet remodeling, which affects PC-BU TEHV safety, challenging their potential for clinical translation. We suggest that bone Marrow mononuclear Cell pre-seeding should not be used in combination with PC-BU TEHVs. A better understanding of Cell-scaffold interaction and in situ remodeling processes is needed to improve transcatheter valve design and polymer absorption rates for a safe and clinically relevant translation of this approach
Sandra L. White - One of the best experts on this subject based on the ideXlab platform.
-
Swainsonine stimulates bone Marrow Cell proliferation and differentiation in different strains of inbred mice
Pharmacological Research, 2003Co-Authors: Oladipo A. Oredipe, K Olden, Sandra L. White, Paulette Furbert-harris, William Green, Ibrahim Laniyan, Debra Parish-gause, Theresa R. Vaughn, Walter M. Griffin, Rajagopalan SridharAbstract:The immunomodulatory alkaloid swainsonine (8αβ-indolizidine-1α,2α,8β-triol) has potential for overcoming the bone Marrow suppressive effects of cancer chemotherapeutic drugs and radiation. The effect of swainsonine on bone Marrow Cellularity was evaluated in four different strains (C57BL/6; C3H-HEN; Balb/C and DBA-2 mice) of inbred mice subjected to multiple doses of the alkaloid. Swainsonine treatment stimulated bone Marrow Cell proliferation in all strains of mice. Examination of the peripheral blood did not reveal any increase in total leukocyte count. In vitro assessment of total colony-forming unit (CFU) capacity of bone Marrow Cells showed a two- to eight-fold increase in swainsonine treated mice of different strains compared to their corresponding controls given sham injections of physiological saline. Swainsonine induced increase in CFU capacity of bone Marrow Cells should find clinical application in cancer treatment with chemotherapeutic agents and radiation.
-
The potential importance of swainsonine in therapy for cancers and immunology.
Pharmacology & Therapeutics, 2002Co-Authors: K Olden, Krzysztof Grzegorzewski, Pascal Breton, Yoshiaki Yasuda, Barry L. Gause, Oladipo A. Oredipe, Sheila A. Newton, Sandra L. WhiteAbstract:Abstract Swainsonine, an indolizidine alkaloid, was initially used in biomedical research as a tool to investigate the biosynthesis and function of asparagine-linked ‘complex’ type oligosaccharide moieties of glycoproteins. Recently, swainsonine has generated interest in its potential use as an anticancer agent with reports that it (i) inhibits tumor growth and metastasis, (ii) augments natural killer (NK) and macrophage-mediated tumor Cell killing, and (ii) stimulates bone Marrow Cell proliferation. The antineoplastic activity of swainsonine can be explained at least in part by augmentation of immune effector mechanisms. The potential application of swainsonine as an anticancer agent is discussed.
Oladipo A. Oredipe - One of the best experts on this subject based on the ideXlab platform.
-
Swainsonine stimulates bone Marrow Cell proliferation and differentiation in different strains of inbred mice
Pharmacological Research, 2003Co-Authors: Oladipo A. Oredipe, K Olden, Sandra L. White, Paulette Furbert-harris, William Green, Ibrahim Laniyan, Debra Parish-gause, Theresa R. Vaughn, Walter M. Griffin, Rajagopalan SridharAbstract:The immunomodulatory alkaloid swainsonine (8αβ-indolizidine-1α,2α,8β-triol) has potential for overcoming the bone Marrow suppressive effects of cancer chemotherapeutic drugs and radiation. The effect of swainsonine on bone Marrow Cellularity was evaluated in four different strains (C57BL/6; C3H-HEN; Balb/C and DBA-2 mice) of inbred mice subjected to multiple doses of the alkaloid. Swainsonine treatment stimulated bone Marrow Cell proliferation in all strains of mice. Examination of the peripheral blood did not reveal any increase in total leukocyte count. In vitro assessment of total colony-forming unit (CFU) capacity of bone Marrow Cells showed a two- to eight-fold increase in swainsonine treated mice of different strains compared to their corresponding controls given sham injections of physiological saline. Swainsonine induced increase in CFU capacity of bone Marrow Cells should find clinical application in cancer treatment with chemotherapeutic agents and radiation.
-
The potential importance of swainsonine in therapy for cancers and immunology.
Pharmacology & Therapeutics, 2002Co-Authors: K Olden, Krzysztof Grzegorzewski, Pascal Breton, Yoshiaki Yasuda, Barry L. Gause, Oladipo A. Oredipe, Sheila A. Newton, Sandra L. WhiteAbstract:Abstract Swainsonine, an indolizidine alkaloid, was initially used in biomedical research as a tool to investigate the biosynthesis and function of asparagine-linked ‘complex’ type oligosaccharide moieties of glycoproteins. Recently, swainsonine has generated interest in its potential use as an anticancer agent with reports that it (i) inhibits tumor growth and metastasis, (ii) augments natural killer (NK) and macrophage-mediated tumor Cell killing, and (ii) stimulates bone Marrow Cell proliferation. The antineoplastic activity of swainsonine can be explained at least in part by augmentation of immune effector mechanisms. The potential application of swainsonine as an anticancer agent is discussed.
K Olden - One of the best experts on this subject based on the ideXlab platform.
-
Swainsonine stimulates bone Marrow Cell proliferation and differentiation in different strains of inbred mice
Pharmacological Research, 2003Co-Authors: Oladipo A. Oredipe, K Olden, Sandra L. White, Paulette Furbert-harris, William Green, Ibrahim Laniyan, Debra Parish-gause, Theresa R. Vaughn, Walter M. Griffin, Rajagopalan SridharAbstract:The immunomodulatory alkaloid swainsonine (8αβ-indolizidine-1α,2α,8β-triol) has potential for overcoming the bone Marrow suppressive effects of cancer chemotherapeutic drugs and radiation. The effect of swainsonine on bone Marrow Cellularity was evaluated in four different strains (C57BL/6; C3H-HEN; Balb/C and DBA-2 mice) of inbred mice subjected to multiple doses of the alkaloid. Swainsonine treatment stimulated bone Marrow Cell proliferation in all strains of mice. Examination of the peripheral blood did not reveal any increase in total leukocyte count. In vitro assessment of total colony-forming unit (CFU) capacity of bone Marrow Cells showed a two- to eight-fold increase in swainsonine treated mice of different strains compared to their corresponding controls given sham injections of physiological saline. Swainsonine induced increase in CFU capacity of bone Marrow Cells should find clinical application in cancer treatment with chemotherapeutic agents and radiation.
-
The potential importance of swainsonine in therapy for cancers and immunology.
Pharmacology & Therapeutics, 2002Co-Authors: K Olden, Krzysztof Grzegorzewski, Pascal Breton, Yoshiaki Yasuda, Barry L. Gause, Oladipo A. Oredipe, Sheila A. Newton, Sandra L. WhiteAbstract:Abstract Swainsonine, an indolizidine alkaloid, was initially used in biomedical research as a tool to investigate the biosynthesis and function of asparagine-linked ‘complex’ type oligosaccharide moieties of glycoproteins. Recently, swainsonine has generated interest in its potential use as an anticancer agent with reports that it (i) inhibits tumor growth and metastasis, (ii) augments natural killer (NK) and macrophage-mediated tumor Cell killing, and (ii) stimulates bone Marrow Cell proliferation. The antineoplastic activity of swainsonine can be explained at least in part by augmentation of immune effector mechanisms. The potential application of swainsonine as an anticancer agent is discussed.
Valeria Santini - One of the best experts on this subject based on the ideXlab platform.
-
Severe hypoxia selects hematopoietic progenitors with stem Cell potential from primary Myelodysplastic syndrome bone Marrow Cell cultures.
Oncotarget, 2018Co-Authors: Erico Masala, Ana Valencia-martinez, Serena Pillozzi, Tommaso Rondelli, Alice Brogi, Alessandro Sanna, Antonella Gozzini, Annarosa Arcangeli, Persio Dello Sbarba, Valeria SantiniAbstract:Myelodysplastic Syndromes (MDS) are clonal neoplasms where stem/progenitor Cells endowed with self-renewal and capable of perpetuating the disease have been demonstrated. It is known that oxygen tension plays a key role in driving normal hematopoiesis and that hematopoietic stem Cells are maintained in hypoxic areas of the bone Marrow (BM). Hypoxia could also regulate leukemic/dysplastic hematopoiesis. We evaluated the stem Cell potential of MDS Cells derived from the BM of 39 MDS patients and selected under severe hypoxia. MDS Cells rescued from hypoxia-incubated cultures were subjected to stem and progenitor Cell assays in vitro, as well as to hematopoietic reconstitution assay in NOD-SCID mice. Incubation in severe hypoxia of Cells explanted from MDS patients selected a Cell subset endowed with stem Cell potential, as determined in vitro. This occurred only from the BM of patients classified as IPSS low/INT-1 risk. Transplantation into NOD-SCID mice confirmed using an in vivo model that severe hypoxia selects a Cell subset endowed with stem Cell potential from bone Marrow mononuclear Cells (BMMC). derived from patients belonging to the IPSS low/int-1 risk group. Data here reported show that Cells endowed with stem Cell potential and capable of adapting to hypoxia and escaping hypoxia-induced apoptosis exist within MDS Cell populations.